Abstract
Omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) from fish and fish oils appear to protect against coronary heart disease: their dietary intake is in fact inversely associated with cardiovascular disease morbidity/mortality in population studies. Recent evidence suggests that at least a part of this protective effect is mediated by a relatively small but significant decrease in blood pressure (BP) level. In fact, ω-3 PUFAs exhibit wide-ranging biological actions that include regulating both vasomotor tone and renal sodium excretion, partly competing with ω-6 PUFAs for common metabolic enzymes and thereby decreasing the production of vasoconstrictor rather than vasodilator and anti-inflammatory eicosanoids. PUFAs also reduce angiotensin-converting enzyme (ACE) activity, angiotensin II formation, Tumor Growth Factor- beta (TGF-β) expression, enhance endothelial nitric oxide (NO) generation and activate the parasympathetic nervous system. The final results are improved vasodilation and arterial compliance of both small and large arteries. Preliminary clinical trials involving normotensive and hypertensive dyslipidaemic patients, diabetics and elderly subjects, confirm this working hypothesis: 3 meta-analyses suggest that PUFAs are able to slightly, but significantly improve arterial hypertension. Future research will clarify if PUFA supplementation could improve the antihypertensive action of specific BP lowering drug classes and of statins.
Keywords: Fish oil, omega 3 fatty acids, polyunsaturated fatty acids, eicosapentaenoic acid, docosahexaenoic acid, blood pressure, hypertension, PUFA
Current Vascular Pharmacology
Title: Omega-3 Polyunsaturated Fatty Acids: Their Potential Role in Blood Pressure Prevention and Management
Volume: 7 Issue: 3
Author(s): Arrigo F.G. Cicero, Sibel Ertek and Claudio Borghi
Affiliation:
Keywords: Fish oil, omega 3 fatty acids, polyunsaturated fatty acids, eicosapentaenoic acid, docosahexaenoic acid, blood pressure, hypertension, PUFA
Abstract: Omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) from fish and fish oils appear to protect against coronary heart disease: their dietary intake is in fact inversely associated with cardiovascular disease morbidity/mortality in population studies. Recent evidence suggests that at least a part of this protective effect is mediated by a relatively small but significant decrease in blood pressure (BP) level. In fact, ω-3 PUFAs exhibit wide-ranging biological actions that include regulating both vasomotor tone and renal sodium excretion, partly competing with ω-6 PUFAs for common metabolic enzymes and thereby decreasing the production of vasoconstrictor rather than vasodilator and anti-inflammatory eicosanoids. PUFAs also reduce angiotensin-converting enzyme (ACE) activity, angiotensin II formation, Tumor Growth Factor- beta (TGF-β) expression, enhance endothelial nitric oxide (NO) generation and activate the parasympathetic nervous system. The final results are improved vasodilation and arterial compliance of both small and large arteries. Preliminary clinical trials involving normotensive and hypertensive dyslipidaemic patients, diabetics and elderly subjects, confirm this working hypothesis: 3 meta-analyses suggest that PUFAs are able to slightly, but significantly improve arterial hypertension. Future research will clarify if PUFA supplementation could improve the antihypertensive action of specific BP lowering drug classes and of statins.
Export Options
About this article
Cite this article as:
Cicero F.G. Arrigo, Ertek Sibel and Borghi Claudio, Omega-3 Polyunsaturated Fatty Acids: Their Potential Role in Blood Pressure Prevention and Management, Current Vascular Pharmacology 2009; 7 (3) . https://dx.doi.org/10.2174/157016109788340659
DOI https://dx.doi.org/10.2174/157016109788340659 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of PPARβ/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology The Genetics of Small-Vessel Disease
Current Medicinal Chemistry The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets Life Threatening and Fatal Contrast Media Reactions: Pathomechanisms, Diagnosis, Prevention and Drug Management
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Supplementation of Creatine and Ribose Prevents Apoptosis and Right Ventricle Hypertrophy in Hypoxic Hearts
Current Pharmaceutical Design Diagnostic Cardiac Catheterization in the Pediatric Population
Current Cardiology Reviews Manipulation and Engineering of Metabolic and Biosynthetic Pathway of Plant Polyphenols
Current Pharmaceutical Design Current Paradigms in COVID-19 Research: Proposed Treatment Strategies, Recent Trends and Future Directions
Current Medicinal Chemistry Diagnosis and Management of Chronic Coronary Artery Disease
Current Cardiology Reviews Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets Editorial (Thematic Issue: Biomarkers of Impaired Innate and Adaptive Immunity in Health and Disease)
Current Immunology Reviews (Discontinued) Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes?
Current Pharmaceutical Design Are Calcium Channel Blockers First-Line Drugs for the Treatment of Hypertension and Cardiovascular Disease?
Current Hypertension Reviews Duloxetine in the Treatment of Depression: An Overview
Central Nervous System Agents in Medicinal Chemistry Is the Vascular System a Main Target for Thyroid Hormones? From Molecular and Biochemical Findings to Clinical Perspectives
Current Vascular Pharmacology Mechanism-Based Inhibitors from Phytomedicine: Risks of Hepatotoxicity and their Potential Hepatotoxic Substructures
Current Drug Metabolism Advances in Stem Cells Transplantation for the Therapy of Parkinson’s Disease
Current Stem Cell Research & Therapy Current Status of Computer-Aided Drug Design for Type 2 Diabetes
Current Computer-Aided Drug Design Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
Current Pharmaceutical Design